TrialPath
← Back to searchRecruiting

Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy

NCT05888909 · Chinese PLA General Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.
Eligibility criteria
Inclusion Criteria: Age ≥ 18 years old, regardless of gender; Type 2 diabetes; Having a complete medical history and clinical data; If the patients with type 2 diabetes combined with CKD underwent renal biopsy, the pathological diagnosis should be clear; Patients voluntarily signs an informed consent form. Exclusion criteria: Incomplete medical history or clinical data; Patients with hereditary kidney disease; Combined urinary tract infection; Merge autoimmune system diseases; Patients with malignant tumor were expected to survive less than 6 months; Pregnancy and lactation.
Study design
Enrollment target: 2000 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-08-01
Estimated completion: 2026-12-31
Last updated: 2023-06-05
Primary outcomes
  • change in estimated glomerular filtration rate (eGFR) from baseline (24months)
Sponsor
Chinese PLA General Hospital · other
With: Beijing Municipal Science & Technology Commission, China-Japan Friendship Hospital, Beijing Friendship Hospital, Beijing Tongren Hospital, Beijing Hospital, Dongzhimen Hospital, Beijing, Xuanwu Hospital, Beijing
Contacts & investigators
ContactZheyi Dong, MD · contact · shengdai26@163.com · +86 010 66935462
All locations (1)
Chinese PLA General HospitalRecruiting
Beijing, China